The Serum Institute of India’s (SII) first indigenously produced quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer will be considered by the Subject expert committee on Wednesday.
Prakash Kumar Singh submitted the qHPV vaccine commercial licence application to the DCGI on June 8. (director of government and regulatory affairs). Singh’s application to the DCGI highlights the vaccine’s antibody response against HPV types in all dosage and age categories.
Also Read: Normal human brain temperature fluctuates far more than previously considered: Study
According to ANI, the vaccine is scheduled to hit the market by the end of 2022. The qHPV vaccine will be India’s first indigenously curated cervical cancer vaccine.
To assure its early availability in the country, the Pune-based Serum Institute of India submitted for market authorisation after completing a phase 2/3 clinical study with the Department of Biotechnology’s assistance.
Follow Medically Speaking on Instagram
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…